Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. (Q48314687)
Jump to navigation
Jump to search
scientific article published on 3 January 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. |
scientific article published on 3 January 2018 |
Statements
1 reference
Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. (English)
1 reference
Shizuya Yamashita
Hidenori Arai
Koutaro Yokote
Jo Satoh
Toyoshi Inoguchi
Jiro Nakamura
Narihito Yoshioka
Yukio Tanizawa
3 January 2018
1 reference